10 February 2021 1 Min Read
Aspen’s offer to cut prices of cancer drugs allows it to avoid EU fine
The EU executive is concerned that Aspen may have charged excessive prices for drugs mainly used to treat leukaemia and other haematological cancers
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In